Severe haematological involvement in children with systemic lupus erythematosus and clinical associations

dc.contributor.authorKisaoglu, Hakan
dc.contributor.authorSener, Seher
dc.contributor.authorDemirbas, Kaan Can
dc.contributor.authorDemir Yigit, Yasemin
dc.contributor.authorGaripcin, Pinar
dc.contributor.authorCoskun, Serkan
dc.contributor.authorKalyoncu, Mukaddes
dc.date.accessioned2026-08-12T17:41:53Z
dc.date.issued2025
dc.departmentFırat Üniversitesi
dc.description.abstractObjectives: To investigate the severe haematological involvement in children with SLE and assess its clinical associations, treatments, outcome and damage accrual. Methods: The medical charts of children with SLE in whom haematological involvement was observed were reviewed. Severe haematological indices were defined as autoimmune haemolytic anaemia with a haemoglobin concentration <8 g/dl, thrombocyte count <30 000/mu L and neutrophil count <500/L. Results: Among the 224 patients included, 102 (45.5%) displayed severe indices, predominantly at the initial involvement, and most frequently as severe anaemia in 54 (24.1%) and severe thrombocytopenia in 45 (20.1%). Disease activity did not differ according to the presence of severe disease indices. In addition, the presence of severe indices at initial involvement did not affect the damage accrual. However, a higher rate of damage (51.1% vs 29.9%, P = 0.002) and steroid-induced damage (28.9% vs 8.2%, P < 0.001) was evident in patients with flares of the haematological system. Regression analysis revealed that rituximab treatment during the initial episode (OR: 4.5, P = 0.006) and the presence of anticardiolipin antibodies (OR: 2.3, P = 0.014) significantly increases the odds for haematological system flare. However, severe indices at initial involvement did not increase the odds of a haematological flare. Conclusion: Severe haematological indices at onset are common but not related with disease outcomes. Prevention of flares is important to improve outcomes, and a more rigorous maintenance strategy would benefit most to children who display haematological indices refractory to conventional immunosuppressants and those with anti-cardiolipin antibodies.
dc.identifier.doi10.1093/rheumatology/keae414
dc.identifier.endpage2161
dc.identifier.issn1462-0324
dc.identifier.issn1462-0332
dc.identifier.issue4
dc.identifier.orcid0000-0003-0620-8155
dc.identifier.orcid0000-0003-0466-0228
dc.identifier.orcid0000-0002-5365-3457
dc.identifier.orcid0000-0002-2122-6952
dc.identifier.orcid0000-0001-6713-6410
dc.identifier.orcid0000-0001-5637-8553
dc.identifier.orcid0000-0001-5038-7539
dc.identifier.pmid39093021
dc.identifier.scopus2-s2.0-105001855304
dc.identifier.scopusqualityQ1
dc.identifier.startpage2153
dc.identifier.urihttps://doi.org/10.1093/rheumatology/keae414
dc.identifier.urihttps://hdl.handle.net/11508/59519
dc.identifier.volume64
dc.identifier.wosWOS:001294642200001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofRheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectchildren
dc.subjectdamage
dc.subjectflare
dc.subjecthaematological involvement
dc.subjectsystemic lupus erythematosus
dc.subjecttreatment
dc.titleSevere haematological involvement in children with systemic lupus erythematosus and clinical associations
dc.typeArticle

Dosyalar